Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BNT152 · 1 trial · 1 indication
TEAEs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.5.0.
| Arm | Type | Description |
|---|---|---|
| Part 1 group A BNT153 | EXPERIMENTAL | Monotherapy dose escalation. |
| Part 1 group B BNT152 | EXPERIMENTAL | Monotherapy dose escalation. |
| Part 2A - BNT152+153 | EXPERIMENTAL | Escalating dose levels up to RP2D |
| Part 2B - BNT152+153 | EXPERIMENTAL | Escalating dose levels up to RP2D |
| Part 2C - BNT152+153 | EXPERIMENTAL | Escalating dose levels up to RP2D |
| Part 2 - BNT152+153 - biomarker cohort | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BNT152 | DRUG | intravenous |
| BNT153 | DRUG | intravenous |
Inclusion Criteria: * Histologically or cytologically confirmed solid tumor that is metastatic (Stage IV) or unresectable and for whom there is no available standard therapy likely to confer clinical benefit, or patient who is not a candidate for such available therapy. If there is no contraindicat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BNT152 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
BNT152 is being developed by BioNTech SE, a biotechnology company publicly traded under the ticker symbol BNTX. The company is conducting clinical trials to evaluate the drug's potential as a treatment for solid tumors.
BNT152 is in Phase 1 clinical development. A Phase 1 dose escalation trial has been completed, which typically focuses on evaluating the drug's safety, tolerability, and dosing. The drug remains investigational and is not yet approved for commercial use.
BNT152 has been studied in one clinical trial, identified as NCT04710043, titled "Dose Escalation Trial of BNT152+153 in Patients With Cancer." This Phase 1 trial enrolled 86 patients with solid tumors and was conducted in the United States and Czechia. The trial has been completed.
BNT152 is not the same as BNT153, but the two are being studied together in a combination trial. The completed Phase 1 trial, NCT04710043, evaluated both BNT152 and BNT153 in patients with cancer, suggesting they are distinct agents being tested in combination.